Եվրոպական Միություն - անգլերեն - EMA (European Medicines Agency)

vbi vaccines b.v. - hepatitis b surface antigen - hepatitis b - vaccines - prehevbri is indicated for active immunisation against infection caused by all known subtypes of the hepatitis b virus in adults. it can be expected that hepatitis d will also be prevented by immunisation with prehevbri as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection. the use of prehevbri should be in accordance with official recommendations.,

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

immunoglobulin g - human; immunoglobulin - hepatitis b; hepatitis b immunoglobulin -

Իսրայել - անգլերեն - Ministry of Health

padagis israel agencies ltd, israel - hepatitis b immunoglobulin - solution for injection - hepatitis b immunoglobulin 220 iu/ml - hepatitis b immunoglobulin - hepatitis b immunoglobulin - for post-exposure prophylaxis such as: - acute exposure to blood containing hbsag, - perinatal exposure of infants born to hbsag-positive mothers, - sexual exposure to hbsag positive persons, - household exposure to persons with acute hbv infections.

Իսրայել - անգլերեն - Ministry of Health

tzamal bio-pharma ltd - hepatitis b immunoglobulin - solution for injection - hepatitis b immunoglobulin 312 iu/ml - hepatitis b immunoglobulin - hepatitis b immunoglobulin - prevention of hepatitis b recurrence following liver transplantation : hepagam b is indicated for the prevetion of hepatitis b recurrence following liver transplantation in hbsag-positive liver transplant patients. hepagam b should be administered intravenously for this indication.postexposure prophylaxis : hepagam b is indicated for the treatment of acute exposure to blood containing hbsag perinatal exposure of infants born to hbsag-positive mothers sexual exposure to hbsag-positive persons and household exposure to persons with acute hbv infection in the following settings: acute exposure to blood containing hbsag following either parenteral exposure (needlestick bite sharps) direct mucous membrane contact (accidental splash) or oral ingestion (pipetting accident) involving hbsag - positive materials such as blood plasma or serum. perinatal exposure of infants born to hbsag-positive mothers infants born to mothers positive for hbsag with or without hbeag. perinatal exposure of infants born to hbsag-positive persons sexual partners of hbsag-positive persons. household exposure to persons with acute hbv infection infants less than 12 months old whose mother or primary caregiver is positive for hbsag. other household contacts with an identifiable blood exposure to the index patient. hepagam b is indicated for intramuscular use only for these post-exposure prophylaxis indications.

Իսրայել - անգլերեն - Ministry of Health

sanofi israel ltd - hepatitis a vaccines - suspension for injection - hepatitis a vaccines 80 units / 0.5 ml - hepatitis a, inactivated, whole virus - hepatitis a, inactivated, whole virus - avaxim 80 u pediatric is indicated for active immunisation against infection caused by hepatitis a virus in children aged from 12 months to 15 years inclusive, who are at risk either of contaminating or spreading infection or of a life threatening disease if infected.

Իսրայել - անգլերեն - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - hepatitis a virus antigen, inactivated - suspension for injection - hepatitis a virus antigen, inactivated 25 units / 0.5 ml - hepatitis a, inactivated, whole virus - hepatitis a, inactivated, whole virus - vaqta is indicated for active pre-exposure prophylaxis against disease caused by hepatitis a virus in children and adolescents 12 months of age and older .

Իսրայել - անգլերեն - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - hepatitis a virus antigen, inactivated - suspension for injection - hepatitis a virus antigen, inactivated 50 u/ml - hepatitis a, inactivated, whole virus - hepatitis a, inactivated, whole virus - vaqta is indicated for active pre-exposure prophylaxis against disease caused by hepatitis a virus in persons 2 years of age and older.

Իռլանդիա - անգլերեն - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - aluminium; hepatitis a antigen - suspension for injection in pre-filled syringe - 720 enzyme-linked immunosorbent assay unit - hepatitis vaccines; hepatitis a, inactivated, whole virus

Իռլանդիա - անգլերեն - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - aluminium; hepatitis a antigen - suspension for injection in pre-filled syringe - 1440 enzyme-linked immunosorbent assay unit - hepatitis vaccines; hepatitis a, inactivated, whole virus

Եվրոպական Միություն - անգլերեն - EMA (European Medicines Agency)

sanofi pasteur - hepatitis b surface antigen, diphtheria toxoid, tetanus toxoid, bordetella pertussis antigens pertussis toxoid filamentous haemagglutinin, poliovirus (inactivated) type 1 (mahoney) type 2 (mef-1) type 3 (saukett), haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) conjugated to tetanus protein - hepatitis b; tetanus; immunization; meningitis, haemophilus; whooping cough; poliomyelitis; diphtheria - vaccines, bacterial and viral vaccines, combined - hexacima (dtap-ipv-hb-hib) is indicated for primary and booster vaccination of infants and toddlers from six weeks of age against diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis and invasive diseases caused by haemophilus influenzae type b (hib).the use of this vaccine should be in accordance with official recommendations.